Refill Extension Without a Prescriber
A patient calls a community pharmacy in Lawton on Friday at 5:40 p.m. She has taken levothyroxine 100 mcg daily for years and has 2 tablets left. Her prescriber retired last month; the covering clinic says no one can authorize refills until a new patient visit in 3 weeks. The label shows no refills remaining. The patient is asymptomatic but worried. The pharmacist has an active collaborative practice agreement with a local physician for diabetes and hypertension management, but it does not mention thyroid disorders. The pharmacist considers giving a 30-day emergency supply and documenting it as a ‘professional courtesy,’ or changing the dose to 88 mcg using the agreement.
1. May the pharmacist provide the 30-day supply or change the dose under the collaborative practice agreement?
Read the worked answer
No, not on these facts. A collaborative practice agreement authorizes only the drug therapy expressly within its scope and only for patients who meet its terms. Diabetes and hypertension authority does not extend to thyroid replacement. Changing levothyroxine to 88 mcg would be prescribing outside the agreement. A 'professional courtesy' 30-day supply is also prescribing unless a specific Oklahoma emergency-supply law applies and every condition is satisfied. Because the patient is asymptomatic and has no urgent harm, the pharmacist should not stretch the agreement or invent authority.
2. What practical options should the pharmacist pursue?
Read the worked answer
- Call the covering clinic and ask for a covering prescriber who can authorize a refill or a bridge supply.
- If no prescriber can be reached, explain the risk of abrupt discontinuation and help the patient get an urgent appointment or telehealth visit.
- Consider whether the patient can be transferred to a pharmacy or clinic with a prescriber who will continue therapy.
- Do not change the dose without a prescriber.
- Document all contacts, the patient's remaining supply, and the advice given.
3. What makes a collaborative practice agreement valid, and would controlled-substance authority change the analysis?
Read the worked answer
A valid collaborative practice agreement should be written, patient-specific or population-specific, define the drugs and conditions covered, require communication with the collaborating physician, and specify documentation and follow-up. Even a valid agreement does not let the pharmacist practice outside its scope. If the patient had a controlled substance instead, the pharmacist would also need to satisfy controlled-substance prescriptive authority and PMP requirements; a noncontrolled agreement would not be enough.